Arbutus Biopharma Corporation - ROE
ABUS
Price:
$4.55
Market Cap:
$898.80M
Arbutus Biopharma Corporation, a biopharmaceutical company operating in the United States, focuses on the discovery and development of novel therapies for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. Central to its HBV product portfolio is AB-729, an innovative RNA interference product candidate delivered subcutaneously. Currently undergoing Phase Ia/Ib clinical trials, AB-729 is engineered to target hepatocytes, effectively inhibiting viral replication and reducing various HBV antigens through its unique covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. Another promising HBV compound is AB-836, an oral capsid inhibitor designed to s...[Read more]
Industry
Biotechnology
IPO Date
2007-07-26
Stock Exchange
NASDAQ
Ticker
ABUS
PE Ratio
[5.48]
ROE
[129.32%]
Current Ratio
[54.26]
Dividend Yield
[0%]
Enterprise Value
[875.72M]
Dividend History
The ROE as of June 2026 (TTM) for Arbutus Biopharma Corporation (ABUS) is 129.32%
According to Arbutus Biopharma Corporation’s latest financial reports and current stock price. The company's current ROE is 129.32%. This represents a change of 869.48% compared to the average of 13.34% of the last 4 quarters.
Arbutus Biopharma Corporation (ABUS) Historical ROE (quarterly & annually)
How has ABUS ROE performed in the past?
The mean historical ROE of Arbutus Biopharma Corporation over the last ten years is -81.78%. The current 129.32% ROE has changed -258.12% with respect to the historical average. Over the past ten years (40 quarters), ABUS's ROE was at its highest in in the March 2026 quarter at 65.22%. The ROE was at its lowest in in the December 2016 quarter at -107.73%.
Average
-81.78%
Median
-56.63%
Minimum
-211.32%
Maximum
-28.52%
Arbutus Biopharma Corporation (ABUS) ROE by Quarter and Year
Discovering the peaks and valleys of Arbutus Biopharma Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.60%
Maximum Annual ROE = -28.52%
Minimum Annual Increase = -75.56%
Minimum Annual ROE = -211.32%
| Year | ROE | Change |
|---|---|---|
| 2025 | -43.75% | -39.08% |
| 2024 | -71.81% | 4.51% |
| 2023 | -68.71% | 35.39% |
| 2022 | -50.75% | 12.78% |
| 2021 | -45.00% | -28.02% |
| 2020 | -62.52% | -70.42% |
| 2019 | -211.32% | 641.04% |
| 2018 | -28.52% | -38.34% |
| 2017 | -46.25% | -75.56% |
| 2016 | -189.21% | 1.60% |
Arbutus Biopharma Corporation (ABUS) Average ROE
How has ABUS ROE performed in the past?
The current ROE of Arbutus Biopharma Corporation (ABUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-61.42%
5-year avg
-56.01%
10-year avg
-81.78%
Arbutus Biopharma Corporation (ABUS) ROE vs. Peers
How is ABUS’s ROE compared to its peers?
Arbutus Biopharma Corporation’s ROE is greater than ARS Pharmaceuticals, Inc. (-153.61%), less than Nanobiotix S.A. (31.23%), greater than GH Research PLC (-19.83%), greater than Tango Therapeutics, Inc. (-41.54%), greater than Bicara Therapeutics Inc. Common Stock (-35.89%), greater than Septerna, Inc. (-9.44%), greater than EyePoint Pharmaceuticals, Inc. (-110.54%), greater than Kura Oncology, Inc. (-141.95%), less than ProKidney Corp. (7.40%), greater than Savara Inc. (-87.19%),
| Company | ROE | Market cap |
|---|---|---|
| -153.61% | $958.28M | |
| 31.23% | $1.84B | |
| -19.83% | $1.52B | |
| -41.54% | $3.48B | |
| -35.89% | $1.27B | |
| -9.44% | $1.63B | |
| -110.54% | $1.14B | |
| -141.95% | $881.53M | |
| 7.40% | $615.34M | |
| -87.19% | $1.13B |
Build a custom stock screener for Arbutus Biopharma Corporation (ABUS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arbutus Biopharma Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Arbutus Biopharma Corporation (ABUS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Arbutus Biopharma Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Arbutus Biopharma Corporation's ROE?
How is the ROE calculated for Arbutus Biopharma Corporation (ABUS)?
What is the highest ROE for Arbutus Biopharma Corporation (ABUS)?
What is the 3-year average ROE for Arbutus Biopharma Corporation (ABUS)?
What is the 5-year average ROE for Arbutus Biopharma Corporation (ABUS)?
How does the current ROE for Arbutus Biopharma Corporation (ABUS) compare to its historical average?